Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...
A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback